美国70岁及以上患者中异基因造血细胞移植的使用日益增加
移植比例从2000年的0.1%升至2013年的3.85%(N=298),2年总生存率和无进展生存率均显著改善,而2年移植相关死亡率维持在33%至35%且无变化。
要点
- 70岁及以上患者异基因移植数量与比例在过去十年显著上升,2013年占3.85%。
- 急性髓系白血病和骨髓增生异常综合征是最常见的疾病指征。
- 2年总生存率从2000-2007年的26%提高至2008-2013年的39%,2年无进展生存率从22%提高至32%。
核心结论
- 过去十年间,70岁及以上患者异基因移植的使用和生存率均有所提高,部分70岁及以上血液系统恶性肿瘤患者应考虑接受移植。
研究设计与样本
- 研究纳入2000年至2013年间在美国接受首次异基因造血细胞移植并报告至国际血液和骨髓移植研究中心的70岁及以上血液系统恶性肿瘤成人患者。
- 研究了移植利用率和移植结局,包括总生存期、无进展生存期和移植相关死亡率。
主要发现
- 移植数量与比例从2000年的0.1%上升至2013年的3.85%(N=298)。
- 急性髓系白血病和骨髓增生异常综合征是最常见的疾病指征。
- 2年总生存率从2000-2007年的26%(95%CI 21%至33%)提高至2008-2013年的39%(95%CI 35%至42%),P < .001。
- 2年无进展生存率从2000-2007年的22%(95%CI 16%至28%)提高至2008-2013年的32%(95%CI 29%至36%),P = .003。
- 2年移植相关死亡率范围为33%至35%,随时间无变化(P = .54)。
临床怎么用
- 部分70岁及以上血液系统恶性肿瘤患者应考虑接受移植(作者结论)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥70 years with hematologic malignancies across the United States. Adults ≥70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied. One thousand one hundred and six patients ≥70 years underwent HCT across 103 transplant centers. The number and proportion of allografts performed in this population rose markedly over the past decade, accounting for 0.1% of transplants in 2000 to 3.85% (N = 298) in 2013. Acute myeloid leukemia and myelodysplastic syndromes represented the most common disease indications. Two-year OS and PFS significantly improved over time (OS: 26% [95% confidence interval (CI), 21% to 33%] in 2000-2007 to 39% [95% CI, 35% to 42%] in 2008-2013, P < .001; PFS: 22% [16% to 28%] in 2000-2007 to 32% [95% CI, 29% to 36%] in 2008-2013, P = .003). Two-year TRM ranged from 33% to 35% and was unchanged over time (P = .54). Multivariable analysis of OS in the modern era of 2008-2013 revealed higher comorbidity by HCT comorbidity index ≥3 (hazard ratio [HR], 1.27; P = .006), umbilical cord blood graft (HR, 1.97; P = .0002), and myeloablative conditioning (HR, 1.61; P = .0002) as adverse factors. Over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥70 years. Select adults ≥70 years with hematologic malignancies should be considered for transplant.
引用
- Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017. PMID: 28674027. doi:10.1182/blood-2017-03-772368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。